PhD Student in Bioethics & Health Policy @JohnsHopkinsSPH/ @Yale alum/ research ethics, FDA policy / Kentuckian/ opinions my own
Baltimore, MD
Joined October 2021
- Tweets44
- Following586
- Followers201
- Likes1.7K
Caleigh Propes (she/her) retweeted
New article published in @JAMAHealthForum that examines and critiques 4 aspects of the current pathwork of regulations covering access to psychedelics––and then provides constructive, sensible, and actionable ways forward for each.
Work led by drug policy expert @CaleighPropes
Was a lot of fun to work on "Gaps in US Psychedelic Policy and How to Close Them" led by @CaleighPropes, with @ExistWell, @MattDEisenberg
jamanetwork.com/journals/jam…
Caleigh Propes (she/her) retweeted
We outline 4 issues exacerbated by the current patchwork of health policies governing access to psychedelics – 1) misleading advertising, 2) unsafe self-directed psychedelic use, 3) informed consent, & 4) coverage & payment– & offer some recommendations.
Caleigh Propes (she/her) retweeted
Was a lot of fun to work on "Gaps in US Psychedelic Policy and How to Close Them" led by @CaleighPropes, with @ExistWell, @MattDEisenberg
jamanetwork.com/journals/jam…
Caleigh Propes (she/her) retweeted
With @CaleighPropes, we expand upon how social value is communicated to participants in psychedelic clinical trials in a short commentary, in response to Earl et al's target article "The Social Value Misconception in Clinical Research" (both linked below)
Caleigh Propes (she/her) retweeted
With @CaleighPropes, @MariannaGrazz, Kyle Patch & @ExistWell, we reviewed ICDs from psilocybin clinical trials across the U.S., and provided a systematic qualitative description of these ICDs.
Caleigh Propes (she/her) retweeted
New paper thread! 🧵
Many have called for “enhanced” informed consent documents (ICD) for psychedelic research & treatments, with growing calls for tailored ICDs in the psychedelic bioethics lit.
But how closely do ICDs in psychedelic clinical trials reflect these proposals?
Caleigh Propes (she/her) retweeted
🧠 Three or more neurology drugs have garnered expedited FDA approvals, sometimes conflicting with advisory panel recommendations. Experts call for more attention to the process between FDA panelists and industry. @washumedicine @AANMember #NeuroTwitter
hubs.la/Q03mLvZ70
Caleigh Propes (she/her) retweeted
We’re happy to share HOPE’s (@psychedelethics) response to the PATH Caucus’s Request for Information (RFI) on psychedelics.
Our response, linked below, highlights key considerations for the field.
@Katherine_Chg, @CaleighPropes, @eddietalksdrugs, @briandavidearp, & @ExistWell
Caleigh Propes (she/her) retweeted
With @CaleighPropes, @eddietalksdrugs, @briandavidearp & @ExistWell, we’re happy to share HOPE’s (@psychedelethics) response to the PATH Caucus's Request for Information (RFI) on psychedelic research for mental health (linked below)
🧵
Caleigh Propes (she/her) retweeted
Sharing aggregate results from pragmatic clinical trials presents ethical & logistical considerations that are distinct from conventional clinical trials, argues Stephanie Morain and colleagues. @smorain @Collaboratory1 @SCTorg #clinicaltrials
Caleigh Propes (she/her) retweeted
Viewpoint: @CaleighPropes, Kayla Mehl, and @SMorain explore the potential of pragmatic clinical trials to improve demographic representativeness and health equity in clinical research.
ja.ma/414aCDP
Caleigh Propes (she/her) retweeted
Ethical considerations for sharing aggregate results from pragmatic clinical trials - Stephanie R Morain, Abigail Brickler, Joe Ali, Pearl O’Rourke, Kayte Spector-Bagdady, Benjamin Wilfond, Vasiliki Rahimzadeh, Caleigh Propes, Kayla Mehl, David Wendler journals.sagepub.com/doi/10.…
Caleigh Propes (she/her) retweeted
Viewpoint: @CaleighPropes, Kayla Mehl, and @SMorain explore the potential of pragmatic clinical trials to improve demographic representativeness and health equity in clinical research.
ja.ma/4fTvouy
Caleigh Propes (she/her) retweeted
Untapped Potential? Representativeness in Pragmatic Clinical Trials | Research, Methods, Statistics - By Caleigh Propes, Kayla Mehl, & Stephanie R. Morain | JAMA jamanetwork.com/journals/jam…
Caleigh Propes (she/her) retweeted
A study co-authored by HPM Doctoral Student @Katherine_Chg aims to identify key elements of an optimal genetic nondiscrimination policy and inform policymakers as they seek to reduce anxieties related to genetic nondiscrimination.
Learn more: jamanetwork.com/journals/jam…
The study highlights the need for binding regulations grounded in human rights to address genetic discrimination. ja.ma/3ZGMbMA
Caleigh Propes (she/her) retweeted
In our new Special Communication, we argue that ethics oversight for #pragmatictrials needs to be fit-for-purpose @bermaninstitute @BSPH_HPM
This Special Communication examines the evolution of ethical oversight for clinical research, highlighting the need for a more nuanced approach to IRB review and informed consent.
ja.ma/3BPi2AB
Caleigh Propes (she/her) retweeted
Thrilled to have worked on this with amazing co-authors @briandavidearp @ExistWell @KRPatch - paper thread soon! Tldr: psychedelics may appear unusual or unique, & their ethical issues exceptional. But might they be more similar to other interventions than first meets the eye?
New work led by @Katherine_Chg, forthcoming in AJOB: Distinctive but not Unique: The Risks of Psychedelic Ethical Exceptionalism buff.ly/4gGKfJK
Caleigh Propes (she/her) retweeted
Viewpoint from @RKMetcalfe and @jayjhpark1: @US_FDA is mandating diversity action plans for trial sponsors but focusing on enrollment quotas could lead to token-istic efforts. ja.ma/4euxqk6
Caleigh Propes (she/her) retweeted
In a new article from our Ethics and Regulatory Core, coauthors @CaleighPropes, @SMorain, and Pearl O'Rourke discuss the key recurring and emerging challenges for pragmatic clinical trials.
➡️ duke.is/y/27ef
Embedded pragmatic clinical trials (ePCTs) can present new challenges and complicate familiar ethical issues in research @SMorain @CaleighPropes @Collaboratory1 #AHAJournals ahajrnls.org/3LwiNjx
Caleigh Propes (she/her) retweeted
Recurring and Emerging Ethical Issues in Pragmatic Clinical Trials by Caleigh Propes, Pearl O'Rourke, Stephanie Morain | Circulation: Cardiovascular Quality and Outcomes ahajournals.org/doi/full/10.…